Back to Results

Scisparc Ltd (SPRC)

SciSparc Ltd. is a clinical-stage pharmaceutical company focused on cannabinoid-based therapies. Its development pipeline includes SCI-110, which is being studied for Tourette syndrome, Alzheimer’s disease, and agitation; SCI-210, which is being developed for autism spectrum disorder and status epilepticus; and CannAmide, a product positioned for inflammation and chronic pain. In addition to its drug candidates, the company sells hemp seed oil-based and related products. SciSparc has partnered with Procaps on the development and commercial manufacture of SCI-110, palmitoylethanolamide oral tablets, and CannAmide softgel capsules. It also has an agreement with The Israeli Medical Center for Alzheimer’s to support a phase IIa trial of SCI-110 in Alzheimer’s disease and agitation, and a collaboration with Clearmind Medicine Inc. Founded in 2004 and headquartered in Tel Aviv-Yafo, Israel, the company was previously known as Therapix Biosciences Ltd. before adopting its current name in January 2021.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-SPRC
$1.45
32.9% Upside
Undervalued
Not available
Not available
Weak
0.0%
November 20, 2026
0.2x
0.9x
633.26 K
5.715 M
25.2%
96.6%
-51.2
71.0%
Valuation • Fair Value

Scisparc Ltd (NASDAQ-SPRC) Fair Value by Valuation Model

Review the available estimates for Scisparc Ltd (NASDAQ-SPRC), including Comps Fair Value.

Primary Valuation Read

Fair Value

$1.45

Estimated upside of 32.9% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

Comps Fair Value

$1.45

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for Scisparc Ltd (NASDAQ-SPRC) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Scisparc Ltd (NASDAQ-SPRC)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

679 K

Current operating scale indicator.

Revenue Forecast

66.844 M

Forward revenue estimate.

EBITDA

-4.828 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Scisparc Ltd (NASDAQ-SPRC) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Scisparc Ltd (NASDAQ-SPRC)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-3.91

No elevated caution signal from this screen.

Altman Z-Score

-51.2

Lower score that deserves closer risk review.

FCF / Net Income

71.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Scisparc Ltd (NASDAQ-SPRC). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Scisparc Ltd (NASDAQ-SPRC)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 20, 2026

Days to Earnings

27

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Scisparc Ltd (NASDAQ-SPRC), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Scisparc Ltd (NASDAQ-SPRC) Stock Forecast & Technical Outlook

Review Scisparc Ltd (NASDAQ-SPRC) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Scisparc Ltd (NASDAQ-SPRC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Scisparc Ltd (NASDAQ-SPRC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Scisparc Ltd (NASDAQ-SPRC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Scisparc Ltd (NASDAQ-SPRC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Scisparc Ltd (NASDAQ-SPRC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Scisparc Ltd (NASDAQ-SPRC)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Scisparc Ltd (NASDAQ-SPRC) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Scisparc Ltd (NASDAQ-SPRC) Stock FAQ

Data-supported answers about Scisparc Ltd (NASDAQ-SPRC), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$1.45
Estimated upside 32.9%
Valuation Rating
Undervalued
Estimated upside of 32.9%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Scisparc Ltd (NASDAQ-SPRC) is $1.45. This implies an estimated upside of 32.9% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 32.9% versus the current market price.

The current financial health read for Scisparc Ltd (NASDAQ-SPRC) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Scisparc Ltd (NASDAQ-SPRC) is November 20, 2026.

The latest available data indicates no current dividend yield for Scisparc Ltd (NASDAQ-SPRC).

The current market capitalization listed for Scisparc Ltd is 633.26 K.

The current enterprise value listed for Scisparc Ltd is 5.715 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Scisparc Ltd is NASDAQ-SPRC, and the stock is listed on NASDAQ.

Scisparc Ltd (NASDAQ-SPRC) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Scisparc Ltd is 25.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Scisparc Ltd is 96.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,135.1 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 635.8 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 358.4 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 294.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 172.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 171.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 125.6 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.5 B
SNY NASDAQ Sanofi ADR Fair Value Bargain Market Cap 99.408 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 65.044 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 45.924 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 44.905 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 36.72 B
ZTS NYSE Zoetis Inc Fair Value Undervalued Market Cap 33.484 B
VTRS NASDAQ Viatris Inc Fair Value Fair Market Cap 20.675 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 13.892 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.251 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.74 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 9.281 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Undervalued Market Cap 7.597 B